La vendita allo scoperto per BrightView Hldgs dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di BrightView Hldgs. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

BrightView Hldgs (NYSE:BV) Azioni, Report sulle vendite allo scoperto

BrightView Hldgs

BrightView Holdings Inc is a provider of commercial landscaping services in the United States. The company provides commercial landscaping services, landscape maintenance, and enhancements to tree care and landscape development. It operates through two segments namely Maintenance Services, and Development Services. The Maintenance Services are self-performed through a national branch network and are route-based in nature. It includes mowing, gardening, mulching and snow removal, water management etc. And Development Services are comprised of sophisticated design, coordination, and installation of landscapes at recognizable corporate, athletic, and university complexes. The company generates a majority of its revenue from Maintenance Services.

BrightView Holdings

BrightView Holdings Inc

BIOVAXYS TECHNOLOGY CORP by BioVaxys Technology Corp.

BioVaxys Technology Corp

BATM ADVANCED COMM by BATM Advanced Communications GBP

BATM Advanced Communications Ltd

MARIE BRIZARD W & S ORD by MARIE BRIZARD WINE & SPIRITS SA

Beaver Coal Ltd

BV Financial Inc

Bluegreen Vacations Holdings Corp Com Cl A

Bluegreen Vacations Holding Corp Class B

Vistry Group PLC

VISTRY GROUP PLC UNSP/ADR by VISTRY GROUP PLC.

BREVILLE GROUP LTD by Breville Group Ltd.

Breville Group Ltd

BREVILLE GRP UNSP/ADR by Breville Group Ltd.

Bold Ventures Inc

Compania De Minas Buenaventura SAA

BAVARIAN NORDIC A S by Bavarian Nordic A/S

Bavarian Nordic AS

BevCanna Enterprises Inc

BAVARIAN NORDIC R/I S/ADR by Bavarian Nordic A/S

Bureau Veritas SA

Bioventus Inc

BRAVURA SOLUTIONS LTD by Bravura Solutions Ltd.

Bravura Solutions Ltd

Iconic Minerals Ltd Ordinary Shares - New

BRAVATEK SOLUTIONS by Bravatek Solutions, Inc.

Bravatek Solutions Inc

BIVICTRIX THERAPEUTICS PL by BIVICTRIX THERAPEUTICS PLC

BUREAU VERITAS SA UNS/ADR by Bureau Veritas SA

News

Offerings

BrightView Holdings Enters Underwriting Agreement For 11.6M Shares Of Common Stock

BrightView Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) ("BrightView") today announced the pricing of an underwritten secondary offering by a selling stockholder affiliated with KKR &amp; Co. Inc. (the "Selling Stockholder") of 11,600,000 shares of common stock of BrightView pursuant to a registration statement filed by BrightView with the U.S. Securities and Exchange Commission (the "SEC"). No shares are being sold by BrightView. The Selling Stockholder will receive all of the proceeds from this offering. The offering is expected to close on June 6, 2025, subject to customary closing conditions. The size of the offering reflects an increase from the 10,000,000 shares of common stock originally proposed to be sold.

BrightView Investor KKR Upsizes Stock Sale to 11.6M Shares (From Prior 10M), Offering Closes June 6

General

BrightView Holdings Files for Offering of 33.1M Shares of Common Stock Offered by Selling Stockholders

Brightview Holdings Files for Mixed Shelf Offering; Size Not Disclosed

I got into the investment business on a steady diet of Graham and Whitman. But that was the 1980s and early 1990s – the golden age of dealmakers and junk bonds, leveraged buyouts and greenmail. 
Long before the players became gentlemanly private equity titans and activist investors, they were raiders, vultures, and even, in one famous book about the RJR deal, barbarians.
Legendary fortunes were made, reputations created and shattered.
All of these high-return, high-flying strategies shared a common thread. Leveraged buyouts, distressed investing and risk arb were all just variations on the value investing theme.
The private equity giants of today are still doing this. Thanks to their quarterly filings, you can copy their investment approach—a strategy that has beaten the markets 4-to-1 since 2001.
Even the creation of the junk bond market was based on Michael Milken&#8217;s studies on the returns from buying undervalued lower-rated bonds, a strategy founded on basic value investing principles.
The big winners in all these strategies took value investing and added debt.
It was like adding nitro to the tank of a stock car. If you could control the vehicle at high speed through the corners, there was no race you couldn&#8217;t win.
Although the golden age of risk arb and the smaller investors&#8217; ability to compete in distressed debt are all behind us, we can still use the combination of debt and value investing to beat the index by a wide margin.
When the 13F filings come out every quarter, most of the short-attention-spans in the market today head for the same filings at the same time.
Warren, Cathie, Stanley, Tepper and Seth still get all the attention.
I may get around to those at some point, but one of the first places I turn is to the leading private equity firms.
Firms like Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>), Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) and KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) still use basic principles of value investing along with a healthy dose of debt to drive massive returns for themselves and their investors.
What most people do not realize is that these firms also have large public securities portfolios, and stealing their ideas has created some massive market-beating opportunities.
If you had bought shares of Mr. Cooper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) when it first appeared in KKR&#8217;s public portfolio in 2018, you could have made almost ten times your money.
Buying shares of AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) when KKR first revealed its position would have resulted in gains of almost seven times your initial cost.
DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) would have delivered gains of 3x in just a few years.
Owning the firm&#8217;s top ten holdings since 2001 would have beaten the market by a 4-to-1 margin.
I do not care what the media darling investors bought last quarter. Tell me what the profit pirates at KKR own, and I can create an opportunity to score massive gains.
The current top ten holdings for KKR are:
BrightSpring Health Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTSG#NASDAQ">BTSG</a>) provides home and community-based health services to complex patients, positioning itself in a niche with long-term demographic tailwinds. The company is newly public and pursuing scale through both organic growth and targeted acquisitions in behavioral and specialty pharmacy segments.
Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) is a global distributor of dental and medical supplies primarily serving small- and mid-sized practices. The company generates stable cash flow and has a long history of disciplined capital deployment, though growth is modest and sensitive to procedure volume trends.
BrightView (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) is the largest commercial landscaping services provider in the U.S., with recurring maintenance revenue making up the majority of its business. Under new leadership, the firm is undergoing a restructuring push to improve margins and reduce debt after years of underperformance.
KKR Real Estate Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KREF#NYSE">KREF</a>) is a commercial mortgage REIT focused on senior loans backed by institutional-grade real estate, primarily in urban markets. It offers a high dividend yield but remains exposed to office market weakness and refinancing risk in a higher-rate environment.
Madison Square Garden Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSGS#NYSE">MSGS</a>) owns marquee sports franchises, including the New York Knicks and Rangers, offering investors a rare asset-backed play on professional sports. Valuation is driven more by franchise appreciation than earnings power, making it a long-duration, event-driven asset.
Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) is a leading cruise operator with a strong focus on premium and upscale offerings across its brand portfolio. The company is rebounding from pandemic-era disruptions, though it still carries significant leverage and remains sensitive to fuel and labor costs.
Bausch Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) is a diversified specialty pharmaceutical company with exposure to eye health, dermatology, and branded generics. However, the company is still burdened by high legacy debt. While it&#8217;s pursuing a turnaround strategy and asset divestitures, legal overhangs and weak cash flow remain headwinds.
FS KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSK#NYSE">FSK</a>) is one of the largest business development companies, focused on senior secured lending to middle-market companies with an emphasis on downside protection. It offers a double-digit yield and strong sponsor backing, though credit quality and NAV stability require close monitoring.
Crescent Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSGY#NYSE">CSGY</a>) is a cash-generating E&amp;P company with a private equity-backed structure and a focus on acquiring and optimizing mature, low-decline assets. The firm maintains a disciplined capital return framework and hedging strategy, making it a defensive upstream play with yield upside.
BridgeBio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) is a commercial-stage biopharmaceutical company developing treatments for genetic diseases and cancers with clear genetic drivers. Its lead drug, Attruby (acoramidis), approved in late 2024 for transthyretin amyloid cardiomyopathy, significantly outperformed sales expectations in its first full quarter, positioning the company as a strong competitor in the cardiomyopathy treatment market.
<h2 class="wp-block-heading">Turn Market Mayhem Into Profit Signals This Memorial Day</h2>
Get real-time portfolio alerts, daily stock ideas, and a suite of pro-grade tools — all in one elite membership. For a limited time, you can access Benzinga Edge at 60% off. Secure Your 60% Memorial Day Discount <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-memorial-day-special/?utm_campaign=mdw-sale&amp;utm_adType=sponsorad&amp;utm_ad=RD052025/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_medium=newsletter">HERE</a>.
Editorial content from our expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

Trading Ideas

BBIO

BTSG

COOP

CSGY

DASH

HSIC

KREF

MSGS

NCLH

The Smart Money Is Buying These 10 Stocks

WIIM

BrightView Holdings shares are trading higher after the company reported better-than-expected Q2 financial results.

BrightView Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) affirms FY2025 sales outlook from $2.75 billion-$2.84 billion to $2.75 billion-$2.84 billion vs $2.78 billion estimate.

Guidance

BrightView Hldgs Affirms FY2025 Sales Guidance of $2.75B-$2.84B vs $2.78B Est

BrightView Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.11 by 27.27 percent. This is a 27.27 percent increase over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $662.60 million which beat the analyst consensus estimate of $645.92 million by 2.58 percent. This is a 1.53 percent decrease over sales of $672.90 million the same period last year.

Earnings

Earnings Beats

BrightView Hldgs Q2 Adj. EPS $0.14 Beats $0.11 Estimate, Sales $662.60M Beat $645.92M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

U.S. stock futures were lower this morning, with the Dow futures falling more than 1,000 points on Thursday.
Shares of RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) fell sharply in today's pre-market trading after the company reported weaker-than-<a href="https://in.benzinga.com/news/earnings/25/04/44616824/rh-q4-earnings-shares-sink-as-revenue-eps-miss-expectations">expected fourth-quarter financial results.</a>
RH reported fourth-quarter revenue of $812.41 million, missing the consensus estimate of $829.56 million, according to Benzinga Pro. The luxury retailer reported fourth-quarter adjusted earnings of $1.58 per share, missing analyst estimates of $1.92 per share.
RH shares dipped 26.6% to $182.97 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>AdvanSix Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASIX#NYSE">ASIX</a>) dipped 29% to $16.00 in pre-market trading.</li>
<li>Hamilton Beach Brands Holding Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBB#NYSE">HBB</a>) fell 24.7% to $15.01 in pre-market trading.</li>
<li>Waton Financial Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTF#NASDAQ">WTF</a>) shares dipped 20.3% to $5.60 in pre-market trading following a 65% decline on Wednesday. Waton Financial announced the closing of initial public offering with simultaneous full exercise of the over-allotment option.</li>
<li>RxSight, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) shares fell 19.2% to $21.00 in pre-market trading after the company announced preliminary first quarter revenue and revised 2025 guidance.</li>
<li>Franklin Covey Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) shares tumbled 14.4% to $23.87 in pre-market trading following weak quarterly sales.</li>
<li>lululemon athletica inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) fell 13% to $246.00 in pre-market trading.</li>
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) fell 12.6% to $19.57 in pre-market trading.</li>
<li>NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) dipped 11.6% to $57.44 in pre-market trading.</li>
<li>Thryv Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) dipped 10.1% to $11.79 in pre-market trading.</li>
<li>BrightView Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) dipped 8.3% to $12.23 in pre-market trading.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) fell 7.4% to $207.25 in pre-market trading. Tigress Financial analyst Ivan Feinseth maintained Apple with a Strong Buy and raised the price target from $295 to $300.</li>
<li>CNB Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCNE#NASDAQ">CCNE</a>) fell 6.8% to $20.97 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell 5.7% to $266.66 in pre-market trading after gaining over 5% on Wednesday.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) dipped 5.3% to $104.56 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44622367/acuity-rh-and-3-stocks-to-watch-heading-into-thursday">Acuity, RH And 3 Stocks To Watch Heading Into Thursday</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Movers

AAPL

ASIX

CCNE

LULU

NVDA

RXST

THRY

TSLA

RH Posts Downbeat Earnings, Joins Apple, Tesla, Nvidia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Primech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMEC#NASDAQ">PMEC</a>) stock increased by 17.6% to $0.92 during Thursday's pre-market session. The market value of their outstanding shares is at $34.9 million. </li>
<li>Globavend Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) stock moved upwards by 12.84% to $0.64. The market value of their outstanding shares is at $9.6 million. </li>
<li>ConnectM Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTM#NASDAQ">CNTM</a>) shares increased by 7.97% to $0.81. The market value of their outstanding shares is at $23.5 million. </li>
<li>Eshallgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHGO#NASDAQ">EHGO</a>) shares rose 7.01% to $1.07. The company's market cap stands at $27.2 million. </li>
<li>FTC Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTCI#NASDAQ">FTCI</a>) shares rose 6.1% to $3.13. The company's market cap stands at $40.2 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>NL Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NL#NYSE">NL</a>) shares moved upwards by 6.09% to $8.35. The market value of their outstanding shares is at $407.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BrightView Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) stock decreased by 32.5% to $9.0 during Thursday's pre-market session. The company's market cap stands at $859.5 million. </li>
<li>Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) stock decreased by 24.71% to $21.0. The company's market cap stands at $277.1 million. The company's, Q2 earnings came out yesterday. </li>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) stock fell 23.85% to $4.79. The company's market cap stands at $2.8 million. </li>
<li>Baiya International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIYA#NASDAQ">BIYA</a>) shares fell 14.26% to $4.45. The market value of their outstanding shares is at $55.6 million. </li>
<li>Covenant Logistics Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVLG#NYSE">CVLG</a>) stock fell 12.59% to $20.21. The market value of their outstanding shares is at $532.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AREB

BIYA

CNTM

CVLG

EHGO

FTCI

PMEC

11 Industrials Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>BrightView Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) shares rose 19.2% to $15.22 during Friday's pre-market session. The company's market cap stands at $1.4 billion. </li>
<li>Lucas GC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCL#NASDAQ">LGCL</a>) shares rose 14.96% to $0.7. The market value of their outstanding shares is at $55.6 million. </li>
<li>Lichen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) stock rose 10.11% to $4.79. The company's market cap stands at $2.8 million. </li>
<li>Satellogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATL#NASDAQ">SATL</a>) shares rose 8.6% to $3.66. The company's market cap stands at $353.6 million. </li>
<li>Huachen AI Parking Mgmt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAI#NASDAQ">HCAI</a>) shares moved upwards by 8.52% to $7.0. The market value of their outstanding shares is at $220.4 million. </li>
<li>Hong Kong Pharma Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HKPD#NASDAQ">HKPD</a>) stock moved upwards by 8.25% to $1.28. The market value of their outstanding shares is at $14.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Solidion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) shares declined by 8.0% to $0.14 during Friday's pre-market session. The market value of their outstanding shares is at $18.3 million. </li>
<li>PS International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) stock fell 7.2% to $0.45. The market value of their outstanding shares is at $10.9 million. </li>
<li>Icon Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICON#NASDAQ">ICON</a>) shares decreased by 6.77% to $0.13. The company's market cap stands at $3.6 million. </li>
<li>Genpact (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) stock decreased by 6.35% to $46.22. The company's market cap stands at $8.1 billion. </li>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) stock decreased by 6.2% to $0.2. </li>
<li>Nuvve Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) shares fell 6.1% to $1.54. The market value of their outstanding shares is at $1.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HCAI

HKPD

ICON

LGCL

LICN

NVVE

PSIG

SATL

12 Industrials Stocks Moving In Friday's Pre-Market Session

Buybacks

BrightView Announces $100M Share Repurchase Program

BrightView shares are trading lower after the company reported worse-than-expected Q1 sales results.

The Q1 earnings report for BrightView Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) was released on Wednesday, February 5, 2025 at 04:10 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
BrightView Hldgs beat estimated earnings by 33.0%, reporting an EPS of $0.04 versus an estimate of $0.03.
Revenue was down $27.50 million from the same period last year.
<h3>Past Earnings Performance</h3>
The company missed on EPS by $0.01 in the last quarter, resulting in a 13.0% drop share price change the following day.
Here's a look at BrightView Hldgs's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.31</td>
<td>0.32</td>
<td>0.07</td>
<td>0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.30</td>
<td>0.32</td>
<td>0.11</td>
<td>0.02</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>723.19M</td>
<td>741.00M</td>
<td>683.80M</td>
<td>645.09M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>728.70M</td>
<td>738.80M</td>
<td>672.90M</td>
<td>626.70M</td>
</tr>
</tbody>
</table>

To track all earnings releases for BrightView Hldgs <a href="https://www.benzinga.com/quote/BV/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BrightView Hldgs Q1 Earnings Report: What Investors Need to Know

BrightView Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) affirms FY2025 sales outlook from $2.75 billion-2.84 billion to $2.75 billion-2.84 billion vs $2.79 billion estimate.

BrightView Hldgs Affirms FY2025 Sales Guidance from $2.75B-2.84B to $2.75B-2.84B vs $2.79B Est

BrightView Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) reported quarterly earnings of $0.04 per share which met the analyst consensus estimate. This is a 100 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $599.20 million which missed the analyst consensus estimate of $611.32 million by 1.98 percent. This is a 4.39 percent decrease over sales of $626.70 million the same period last year.

Earnings Misses

BrightView Hldgs Q1 Adj $0.04, Inline, Sales $599.20M Miss $611.32M Estimate

BrightView Hldgs Q1 2025 Adj EPS $0.04, Inline, Sales $599.20M Miss $611.32M Estimate

Comments

BrightView Hldgs

Vendite allo scoperto

BrightView Hldgs (NYSE:BV) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO